A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Clinical Trial Grant
Awarded By
Astellas Pharma Global Development, Inc
Start Date
February 14, 2024
End Date
February 14, 2029
Awarded By
Astellas Pharma Global Development, Inc
Start Date
February 14, 2024
End Date
February 14, 2029